
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 35 kDa under reducing (R) condition (SDS-PAGE).
>90% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human Tyk2 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Peficitinib | ASP-015K; JNJ-54781532 | Approved | Astellas Pharma Inc | Smyraf | Japan | Arthritis, Rheumatoid | Astellas Pharma Inc | 2019-03-29 | Arthritis, Rheumatoid; Psoriasis; Colitis, Ulcerative | Details |
| Deucravacitinib | BMS-986165; BMS-986165-01 | Approved | Bristol-Myers Squibb Company | Sotyktu | Japan | Psoriasis | Bristol-Myers Squibb Kk | 2022-09-09 | Lupus Vulgaris; Inflammatory Bowel Diseases; Alopecia Areata; Lupus Erythematosus, Discoid; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Liver Diseases; Psoriasis; Lupus Erythematosus, Systemic; Colitis, Ulcerative; Arthritis, Psoriatic; Inflammation; Crohn Disease; Plaque psoriasis | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| ABBV-712 | ABBV-712 | Phase 1 Clinical | Abbvie Inc | Psoriasis | Details |
| MAX-40070 | MAX-40070 | Phase 1 Clinical | Maxinovel Pty Ltd | Alopecia Areata | Details |
| GLPG-3121 | GLPG-3121 | Phase 1 Clinical | Galapagos Nv | Details | |
| BGB-23339 | BGB-23339 | Phase 1 Clinical | Beigene Ltd | Autoimmune Diseases; Plaque psoriasis | Details |
| OST-122 | OST-122 | Phase 2 Clinical | Oncostellae Sl | Colitis, Ulcerative | Details |
| TLL-018 | TLL-018 | Phase 2 Clinical | Tll Pharmaceutical Llc | Chronic Urticaria; Arthritis, Rheumatoid; Psoriasis; Colitis, Ulcerative; Urticaria | Details |
| TQ-05105 | TQ-05105 | Phase 2 Clinical | Lianyungang Runzhong Pharmaceutical Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Centaurus Biopharma Co Ltd | Myeloproliferative Disorders; Neoplasms; Graft vs Host Disease; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic | Details |
| ICP-488 | ICP-488 | Phase 1 Clinical | InnoCare Pharma Ltd | Autoimmune Diseases; Psoriasis; Plaque psoriasis | Details |
| ESK-001 | ESK-001 | Phase 2 Clinical | Alumis Inc | Autoimmune Diseases; Psoriasis | Details |
| QY201 | QY-201; QY201 | Phase 2 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Dermatitis, Atopic | Details |
| ICP-332 | ICP-332 | Phase 1 Clinical | InnoCare Pharma Ltd | Psoriasis; Dermatitis, Atopic | Details |
| Brepocitinib | PF-06700841-15; PF-6700841; PF-841; PF-06700841 | Phase 3 Clinical | Pfizer Inc | Alopecia; Alopecia Areata; Dermatomyositis; Kidney Diseases; Lupus Erythematosus, Systemic; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Hidradenitis Suppurativa; Dermatitis, Atopic; Vitiligo; Crohn Disease | Details |
| Ropsacitinib | PF-06826647 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Psoriasis; Colitis, Ulcerative; Hidradenitis Suppurativa | Details |
| VTX-958 | VTX-958 | Phase 2 Clinical | Ventyx Biosciences Inc | Plaque psoriasis | Details |
| NDI-034858 | NDI-034858 | Phase 2 Clinical | Nimbus Therapeutics LLC | Psoriasis; Arthritis, Psoriatic; Plaque psoriasis | Details |
| GLPG-3667 | GLPG-3667 | Phase 1 Clinical | Galapagos Nv | Psoriasis | Details |
This web search service is supported by Google Inc.




